608137-33-3|Lisdexamfetamine dimesylate|(S)-6-amino-2-(((S)-1-phenylpropan-2-yl)amino)hexanamide, dimesylate|-范德生物科技公司

Lisdexamfetamine dimesylate

NMR下载 COA and HPLC MSDS下载
names：
(S)-6-amino-2-(((S)-1-phenylpropan-2-yl)amino)hexanamide, dimesylate
CAS号：
608137-33-3
MDL Number：
MF(分子式)： C15H25N3O MW(分子量)： 263.38
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Lisdexamfetamine dimesylate
英文别名	Vyvanse. N(2S)1phenylpropan2ylLlysinamide dimesylate
CAS号	608137-33-3
Inchi	InChI=1S/C15H25N3O.2CH4O3S/c1-12(11-13-7-3-2-4-8-13)18-14(15(17)19)9-5-6-10-16;21-5(2,3)4/h2-4,7-8,12,14,18H,5-6,9-11,16H2,1H3,(H2,17,19);21H3,(H,2,3,4)/t12-,14-;;/m0../s1
InchiKey	QJLWWRIBAQLZDR-FORAGAHYSA-N
分子式 Formula	C15H25N3O
分子量 Molecular Weight	263.38
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Lisdexamfetamine dimesylate(CAS:608137-33-3 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Lisdexamphetamine (L-lysine-D-amphetamine; sold as Vyvanse) is a psychostimulant prodrug of the phenethylamine and amphetamine chemical classes. Its molecular structure consists of dextroamphetamine coupled with the essential amino acid L-lysine. Lisdexamfetamine dimesylate is discontinued (DEA controlled substance).
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Findling RL. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. J Child Adolesc Psychopharmacol. 2010 Dec;20(6):503-1[1]PubMed PMID: 21186969; PubMed Central PMCID: PMC3005278.

[2]Wigal SB, Chae S, Patel A, Steinberg-Epstein R. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. Semin Pediatr Neurol. 2010 Dec;17(4):230-6. PubMed PMID: 21183129.

[3] Katic A, Ginsberg L, Jain R, Adeyi B, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Turgay A, Findling RL. Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate. J Atten Disord. 2010 Dec 20. [Epub ahead of print] PubMed PMID: 21173426.

[4] Wigal SB, Kollins SH, Childress AC, Adeyi B. Efficacy and tolerability of Lisdexamfetamine Dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child Adolesc Psychiatry Ment Health. 2010 Dec 14;4(1):32. [Epub ahead of print] PubMed PMID: 21156071.

[5] Ermer JC, Adeyi BA, Pucci ML. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs. 2010 Dec 1;24(12):1009-25. doi: 10.2165/11539410-000000000-00000. PubMed PMID: 21090837.

6: Elbe D, Macbride A, Reddy D. Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry. 2010 Nov;19(4):303-14. PubMed PMID: 21037922; PubMed Central PMCID: PMC2962544.7: Dew RE, Kollins SH. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother. 2010 Dec;11(17):2907-13. Epub 2010 Oct 28. PubMed PMID: 20979573.8: Wigal SB, Maltas S, Crinella F, Stehli A, Steinhoff K, Lakes K, Schuck S. Reading Performance as a Function of Treatment With Lisdexamfetamine Dimesylate in Elementary School Children Diagnosed With ADHD. J Atten Disord. 2010 Oct 26. [Epub ahead of print] PubMed PMID: 20978273.9: Manos MJ, Brams M, Childress AC, Findling RL, Lopez FA, Jensen PS. Changes in Emotions Related to Medication Used to Treat ADHD. Part I: A Literature Review. J Atten Disord. 2010 Sep 28. [Epub ahead of print] PubMed PMID: 20876887.10: Wigal SB, Jun A, Wong AA, Stehli A, Steinberg-Epstein R, Lerner MA. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate? Postgrad Med. 2010 Sep;122(5):27-34. PubMed PMID: 20861585.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开